Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 5.7% – Here’s Why

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) fell 5.7% during mid-day trading on Monday . The company traded as low as $36.41 and last traded at $36.19. 266,106 shares were traded during mid-day trading, a decline of 18% from the average session volume of 324,345 shares. The stock had previously closed at $38.37.

Analysts Set New Price Targets

A number of research firms have issued reports on SUPN. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals in a research note on Monday, January 6th. They set an “overweight” rating and a $57.00 price objective on the stock.

Supernus Pharmaceuticals Price Performance

The business has a fifty day moving average of $37.14 and a 200-day moving average of $34.53. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of 34.92 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. The firm had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals’s revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.29) earnings per share. As a group, research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current year.

Insider Buying and Selling

In related news, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the transaction, the director now owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 154,913 shares of company stock valued at $5,687,914. 9.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its stake in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 398 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 352 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Supernus Pharmaceuticals during the 4th quarter valued at about $72,000. Venturi Wealth Management LLC purchased a new position in Supernus Pharmaceuticals during the 4th quarter valued at about $92,000. Finally, KBC Group NV grew its stake in Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after acquiring an additional 929 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.